Articles
| Open Access |
DOI: EFFECTS OF PERINDOPRIL INITIATION ON SERUM CREATININE AND POTASSIUM LEVELS FOLLOWING ACUTE CORONARY SYNDROME (ACS)
Ezazaya Sukesh , Pharmacy Department, Hospital Sultan Ismail, Johor, MalaysiaAbstract
Perindopril, an angiotensin-converting enzyme (ACE) inhibitor, is commonly prescribed as a cardioprotective medication following acute coronary syndrome (ACS). However, concerns have been raised regarding its potential impact on renal function and serum potassium levels. This study aimed to investigate the effects of perindopril initiation on serum creatinine and potassium levels in patients with ACS.
Keywords
Perindopril, Acute coronary syndrome (ACS), Serum creatinine
References
D. P. Bicket, “Using ACE inhibitors appropriately,” American family physician, vol. 66, issue 3, pp. 461-8, 2002.
The Europa Trial Investigators, “Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery diseases: a randomised double blind, placebo controlled, multicenter trial (the EUROPA study),” The Lancet, vol. 362, issue 9, pages 782-88, 2003.
R. Ferrari, “Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized perindopril and remodeling in elderly with acute myocardial infarction (PREAMI) study,” Arch Intern Med, vol. 166, issue 6, pp. 659-66, 2006.
Management of Chronic Kidney Disease in Adults, 2nd ed., Ministry of Health., Putrajaya., WP, 2018.
Hypertension in Adults: diagnosis and management, National Institute for Health and Clinical Excellence., 2011.
Chronic kidney disease in adults: assessment and management, National Institute for Health and Clinical Excellence., 2014.
M. Schmidt, K. E. Mansfield, K. Bhaskaran, D. Nitsch, H. T. Sørensen, L. Smeeth, L. A. Tomlinson, “Adherence to guidelines for creatinine and potassium monitoring and discontinuation following renin-angiotensin system blockade: a UK general practice-based cohort study,” BMJ Open, 2017.
J. S. Hurley, M. Roberts, L. I. Solberg, M. J. Gunter, W. W. Nelson, L. Young, F. J. Frost, “Laboratory safety monitoring of chronic medications in ambulatory care settings,” J Gen Intern Med, vol. 20, issue 4, pages 331-333, 2005.
J. E. Bootsma, M. F. W. Herwaarden, A. L. M. Verbeek, P. Füssenich, P. A. G. M. D. Smet, M. G. O. Rikkert, C. Kramers, “Adherence to biochemical monitoring recommendations in patients starting with renin angiotensin system inhibitors: a retrospective cohort study in the Netherlands,” Drug Saf, vol. 34, issue 7, pages 605-14, 2011.
G. L. Bakris, M. R. Weir, “ Angiotensin-converting enzyme inhibitor– associated elevations in serum creatinine: is this a cause for concern?,” Arch Intern Med., vol. 160, issue 5, pages 685-93, 2000.
Article Statistics
Copyright License
Copyright (c) 2023 The American Journal of Medical Sciences and Pharmaceutical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.